10-Q: Atossa Therapeutics Reports Progress on (Z)-Endoxifen Development, Q1 2024 Financial Results

Atossa Therapeutics, a clinical-stage biopharmaceutical company, reported progress in its (Z)-endoxifen development programs and financial results for the first quarter of 2024.

Summary

• Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for breast cancer and other breast conditions.
• The company's lead drug candidate is oral (Z)-endoxifen, which is being developed for both the prevention and treatment of breast cancer.
• Atossa reported a net loss of $5.9 million for Q1 2024, compared to a net loss of $6.3 million in Q1 2023.
• The company ended the quarter with $84 million in cash and cash equivalents.
• Research and development expenses increased slightly to $3.7 million in Q1 2024, primarily due to increased spending on clinical and non-clinical trials.
• General and administrative expenses decreased to $3.2 million in Q1 2024, mainly due to a decrease in non-cash stock-based compensation.
• Atossa believes it has sufficient cash on hand to fund its projected operating requirements for at least the next 12 months.

Sentiment

Score: 4

Explanation: The company is making progress in its clinical trials, but ongoing losses, the need for future capital raises, and patent challenges create uncertainty.

Positives

• Progress is being made in the development of (Z)-endoxifen, with multiple Phase 2 trials underway.
• The company has a strong cash position, with $84 million in cash and cash equivalents as of March 31, 2024.
• Atossa believes it has sufficient cash to fund operations for at least the next 12 months.
• The company is actively exploring new opportunities to expand its pipeline.
• Enrollment was completed in January 2024 for the Phase 2 I-SPY clinical trial.
• On April 15, 2024, a new study was initiated to evaluate (Z)-endoxifen in combination with abemaciclib (VERZENIO ).
• The company received approximately $0.2 million from the exercises of warrants resulting in the issuance of 203,750 shares of common stock during the three months ended March 31, 2024.

Negatives

• Atossa has a history of operating losses and has not yet established an ongoing source of revenue.
• The company reported a net loss of $5.9 million for Q1 2024.
• Research and development expenses increased in Q1 2024 compared to the prior year period.
• The company is no longer reasonably assured that its full Australian R&D tax incentive program position would be sustained under audit, resulting in a $1.8 million liability.
• A Petition for Post Grant Review has been filed with the U.S. Patent and Trademark Office seeking to invalidate one of the company's issued patents.
• The Indian Pharmaceutical Alliance filed a Pre-Grant Opposition against one of the company's pending Indian Patent Applications.

Risks

• The company will need to raise substantial additional capital in the future to fund its operations.
• There is no guarantee that (Z)-endoxifen or any other product candidates will be approved for marketing.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company is dependent on third-party service providers for a number of critical operational activities.
• Clinical trials may be delayed or may fail to demonstrate the efficacy and safety of product candidates.
• The company may be unable to protect its intellectual property rights.
• The company may be subject to product liability claims.
• Changes in laws and regulations could adversely affect the company's business.
• The company's stock price is volatile and may decline.
• The company may be unable to maintain its listing on the Nasdaq Capital Market.
• The ownership of the company's common stock may become concentrated among a small number of stockholders.

Future Outlook

The company believes it has sufficient cash on hand to fund its projected operating requirements for at least the next 12 months, but may need to raise additional capital in the future.

Management Comments

• Our business strategy is to advance our programs through clinical studies, including potentially with partners, and opportunistically add programs in areas of high unmet medical need through acquisition, minority investment, collaboration or internal development.

Industry Context

Atossa is developing (Z)-endoxifen for breast cancer, a large and growing market with significant unmet medical need. The company's focus on both prevention and treatment differentiates it from some competitors. The development of (Z)-endoxifen for MBD is a novel approach, addressing an emerging public health issue.

Comparison to Industry Standards

• Atossa's net loss of $5.9 million for Q1 2024 is not unusual for a clinical-stage biopharmaceutical company.
• Many other companies in this space, such as Olema Pharmaceuticals, Context Therapeutics, and G1 Therapeutics, are also operating at a loss while they develop their pipelines.
• For example, Olema Pharmaceuticals reported a net loss of $25.7 million for Q1 2024, Context Therapeutics reported a net loss of $6.7 million for Q1 2024, and G1 Therapeutics reported a net loss of $17.7 million for Q1 2024.
• Atossa's cash position of $84 million is relatively strong compared to some peers, providing a runway for continued development.
• Atossa's focus on (Z)-endoxifen as a potential treatment for both breast cancer and MBD is a unique approach compared to many competitors who are focused solely on treatment.

Legal Proceedings

• On August 18, 2023, Intas Pharmaceuticals LTD. filed a Petition for Post Grant Review (PGR) with the U.S. Patent and Trademark Office, seeking to invalidate one of the company's issued patents.
• On September 28, 2023, the Indian Pharmaceutical Alliance filed a Pre-Grant Opposition against one of the company's pending Indian Patent Applications.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; stock price may be volatile.
• Employees: Potential for growth and expansion if the company is successful; job security may be at risk if the company is unable to raise sufficient capital.
• Patients: Potential for new and improved treatments for breast cancer and other breast conditions.
• Suppliers: Potential for increased business if the company's products are successful.
• Creditors: Potential for losses if the company is unable to repay its debts.

Next Steps

• Continue enrollment and treatment in the EVANGELINE study.
• Report primary data from the Karisma-(Z)-endoxifen study in the second half of 2024.
• Continue to evaluate (Z)-endoxifen in combination with abemaciclib in the I-SPY 2 trial.
• Continue to seek partnerships and explore opportunities to expand the pipeline.

Key Dates

Keywords

Atossa Therapeutics, Z-endoxifen, breast cancer, mammographic breast density, MBD, neoadjuvant treatment, clinical trials, Phase 2, oncology, biopharmaceutical, ER+ HER2-, DCIS, FDA, IND